Clinical Cancer Research Versailles No Abst AACR Membership
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shotelersuk, K.
Right arrow Articles by Mutirangura, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shotelersuk, K.
Right arrow Articles by Mutirangura, A.
Clinical Cancer Research Vol. 6, 1046-1051, March 2000
© 2000 American Association for Cancer Research

Molecular Oncology, Markers, Clinical Correlates

Epstein-Barr Virus DNA in Serum/Plasma as a Tumor Marker for Nasopharyngeal Cancer1

Kanjana Shotelersuk2, Chonlakiat Khorprasert2, Sairoong Sakdikul, Wichai Pornthanakasem, Narin Voravud and Apiwat Mutirangura3

Radiotherapy Section, Department of Radiology [K. S., C. K.], Genetics Unit, Department of Anatomy [S. S., A. M.], Department of Microbiology [W. P.], and Medical Oncology Unit, Department of Medicine [N. V.], Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand

Nasopharyngeal cancer (NPC) constitutes a type of carcinoma encountered frequently in Southern China, among Eskimos of the Arctic region, and to a lesser extent in Southeast Asia. Because EBV DNA present in plasma or serum of NPC patients has proven to represent a promising noninvasive tumor marker, the present study was designed to determine the incidence of serum/plasma EBV DNA by nested PCR during various disease management stages. By this method, we could detect EBV DNA in plasma/serum of 98 of 167 NPC patients prior to treatment, compared with 10 of 77 samples derived from healthy blood donors serving as controls, with a similar prevalence observed in plasma versus serum. Investigation of 13 patients subjected to radiotherapy revealed plasma EBV DNA to persist in the plasma of one case, whereas among the remaining patients, it had vanished during the early phase of treatment. Finally, with 52 samples derived from 37 NPC patients during follow-up, we established 100% specificity and 0% false-positive rate for plasma DNA detection by nested PCR. Moreover, we subjected 24 known EBV DNA-positive serum samples to DNase digestion prior to DNA extraction and amplification to differentiate between free and encapsulated viral DNA, which demonstrated complete absence of the human ß-globin genomic DNA in contrast to EBV DNA detectable in 14 samples. In conclusion, applying this noninvasive method, serum/plasma EBV DNA constitutes a reliable tumor marker prior to, during, and after treatment of NPC.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
Q.-T. Le, C. D. Jones, T.-K. Yau, H. A. Shirazi, P. H. Wong, E. N. Thomas, B. K. Patterson, A. W.M. Lee, and J. L. Zehnder
A Comparison Study of Different PCR Assays in Measuring Circulating Plasma Epstein-Barr Virus DNA Levels in Patients with Nasopharyngeal Carcinoma
Clin. Cancer Res., August 15, 2005; 11(16): 5700 - 5707.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
S. J. C. Stevens, S. A. W. M. Verkuijlen, B. Hariwiyanto, Harijadi, J. Fachiroh, D. K. Paramita, I. B. Tan, S. M. Haryana, and J. M. Middeldorp
Diagnostic Value of Measuring Epstein-Barr Virus (EBV) DNA Load and Carcinoma-Specific Viral mRNA in Relation to Anti-EBV Immunoglobulin A (IgA) and IgG Antibody Levels in Blood of Nasopharyngeal Carcinoma Patients from Indonesia
J. Clin. Microbiol., July 1, 2005; 43(7): 3066 - 3073.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
J.-C. Lin, W.-Y. Wang, K. Y. Chen, Y.-H. Wei, W.-M. Liang, J.-S. Jan, and R.-S. Jiang
Quantification of Plasma Epstein-Barr Virus DNA in Patients with Advanced Nasopharyngeal Carcinoma
N. Engl. J. Med., June 10, 2004; 350(24): 2461 - 2470.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
S. M. Krishna, S. James, J. Kattoor, and P. Balaram
Serum EBV DNA as a Biomarker in Primary Nasopharyngeal Carcinoma of Indian Origin
Jpn. J. Clin. Oncol., June 1, 2004; 34(6): 307 - 311.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
S.-f. Leung, J. S. Tam, A. T.C. Chan, B. Zee, L. Y.S. Chan, D. P. Huang, A. Van Hasselt, P. J. Johnson, and Y.M. D. Lo
Improved Accuracy of Detection of Nasopharyngeal Carcinoma by Combined Application of Circulating Epstein-Barr Virus DNA and Anti-Epstein-Barr Viral Capsid Antigen IgA Antibody
Clin. Chem., February 1, 2004; 50(2): 339 - 345.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. S. Wong, D. L.-W. Kwong, J. S.-T. Sham, S. W. Tsao, W. I. Wei, Y. L. Kwong, and A. P.-W. Yuen
Promoter Hypermethylation of High-in-normal 1 Gene in Primary Nasopharyngeal Carcinoma
Clin. Cancer Res., August 1, 2003; 9(8): 3042 - 3046.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K.C. A. Chan, J. Zhang, A. T.C. Chan, K. I.K. Lei, S.-F. Leung, L. Y.S. Chan, K. C.K. Chow, and Y.M. D. Lo
Molecular Characterization of Circulating EBV DNA in the Plasma of Nasopharyngeal Carcinoma and Lymphoma Patients
Cancer Res., May 1, 2003; 63(9): 2028 - 2032.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. K. C. Ngan, T. T. C. Yip, W.-W. Cheng, J. K. C. Chan, W. C. S. Cho, V. W. S. Ma, K.-K. Wan, S.-K. Au, C.-K. Law, and W.-H. Lau
Circulating Epstein-Barr Virus DNA in Serum of Patients with Lymphoepithelioma-like Carcinoma of the Lung: A Potential Surrogate Marker for Monitoring Disease
Clin. Cancer Res., April 1, 2002; 8(4): 986 - 994.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
A. Forastiere, W. Koch, A. Trotti, and D. Sidransky
Head and Neck Cancer
N. Engl. J. Med., December 27, 2001; 345(26): 1890 - 1900.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. M. D. Lo, W. Y. Chan, E. K. W. Ng, L. Y. S. Chan, P. B. S. Lai, J. S. Tam, and S. C. S. Chung
Circulating Epstein-Barr Virus DNA in the Serum of Patients with Gastric Carcinoma
Clin. Cancer Res., July 1, 2001; 7(7): 1856 - 1859.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J.-C. Lin, K. Y. Chen, W.-Y. Wang, J.-S. Jan, W.-M. Liang, C.-S. Tsai, and Y.-H. Wei
Detection of Epstein-Barr Virus DNA in the Peripheral-Blood Cells of Patients With Nasopharyngeal Carcinoma: Relationship to Distant Metastasis and Survival
J. Clin. Oncol., May 15, 2001; 19(10): 2607 - 2615.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
S. J. C. Stevens, I. Pronk, and J. M. Middeldorp
Toward Standardization of Epstein-Barr Virus DNA Load Monitoring: Unfractionated Whole Blood as Preferred Clinical Specimen
J. Clin. Microbiol., April 1, 2001; 39(4): 1211 - 1216.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
Y. M. D. Lo, A. T. C. Chan, L. Y. S. Chan, S.-F. Leung, C.-W. Lam, D. P. Huang, and P. J. Johnson
Molecular Prognostication of Nasopharyngeal Carcinoma by Quantitative Analysis of Circulating Epstein-Barr Virus DNA
Cancer Res., December 1, 2000; 60(24): 6878 - 6881.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.